Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00000358

Enrollment

Registered

1999-09-21

Start date

Unknown

Completion date

Unknown

Last updated

2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders, Substance-Related Disorders

Brief summary

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Interventions

DRUGLofexidine

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

21 Years to 59 Years

Healthy volunteers

Inclusion criteria

Please contact site for information.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026